HER2 therapies and gastric cancer: A step forward

被引：58

作者：

de Mello, Ramon Andrade ^{[1
,2
]}

Marques, Andrea Marin ^{[3
]}

Araujo, Antonio ^{[1
]}

机构：

[1] Portuguese Oncol Inst, Dept Med Oncol, Gastrointestinal Unit, P-4200072 Oporto, Portugal

[2] Univ Porto, FMUP Fac Med, Dept Med, P-4200319 Oporto, Portugal

[3] Ctr Hosp Medio Ave, Unidade Santo Tirso, P-4780371 Oporto, Portugal

来源：

WORLD JOURNAL OF GASTROENTEROLOGY | 2013年 / 19卷 / 37期

关键词：

Gastric cancer; Trastuzumab; c-Met; Human epidermal growth factor receptor 2; Lapatinib; Pertuzumab; BREAST-CANCER; PHASE-II; C-MET; ESOPHAGOGASTRIC ADENOCARCINOMA; TRASTUZUMAB; PERTUZUMAB; CHEMOTHERAPY; SURVIVAL; OVEREXPRESSION; AMPLIFICATION;

D O I：

10.3748/wjg.v19.i37.6165

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

100201 [内科学];

摘要：

Gastric cancer usually is diagnosed in advanced stages and thus current medical practice affords limited therapeutic options. However, recent studies established the role of human epidermal growth factor receptor 2 (HER2) in clinical management. Trastuzumab, an anti-HER2 monoclonal antibody, acquired a main role in advanced gastric cancer harboring HER2 overexpression and/or amplification improving survival to 17.1 mo according to trastuzumab for gastric cancer phase III trial results. Also, new promising drugs, such as c-Met inhibitors, are in development and assessment for this setting. Certainly, novel drugs will emerge in the next feel years for help oncologists improve clinical management of advanced gastric cancer providing higher survival and quality of life. In this mini-review we will discuss some issues in this regard and provide an actual overview of this setting. (c) 2013 Baishideng. All rights reserved.

引用

页码：6165 / 6169

页数：5

共 50 条

[1]

Prognostic significance of HER2/neu expression in gastric cancer [J].

Ananiev, Julian ;

Gulubova, Maya ;

Manolova, Irena ;

Tchernev, Georgi .

WIENER KLINISCHE WOCHENSCHRIFT, 2011, 123 (13-14) :450-454

[2]

Bang Y, 2009, J CLIN ONCOL, V27

[3]

Bang YJ, 2010, LANCET, V376, P1302

[4]

Bang YJ, 2009, J CLIN ONCOL, V27, p18s

[5]

Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer [J].

Barok, Mark ;

Tanner, Minna ;

Koninki, Katri ;

Isola, Jorma .

CANCER LETTERS, 2011, 306 (02) :171-179

[6]

Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients [J].

Barros-Silva, J. D. ;

Leitao, D. ;

Afonso, L. ;

Vieira, J. ;

Dinis-Ribeiro, M. ;

Fragoso, M. ;

Bento, M. J. ;

Santos, L. ;

Ferreira, P. ;

Rego, S. ;

Brandao, C. ;

Carneiro, F. ;

Lopes, C. ;

Schmitt, F. ;

Teixeira, M. R. .

BRITISH JOURNAL OF CANCER, 2009, 100 (03) :487-493

[7]

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer [J].

Baselga, Jose ;

Cortes, Javier ;

Kim, Sung-Bae ;

Im, Seock-Ah ;

Hegg, Roberto ;

Im, Young-Hyuck ;

Roman, Laslo ;

Pedrini, Jose Luiz ;

Pienkowski, Tadeusz ;

Knott, Adam ;

Clark, Emma ;

Benyunes, Mark C. ;

Ross, Graham ;

Swain, Sandra M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) :109-119

[8]

CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer [J].

Baselga, Jose ;

Swain, Sandra M. .

CLINICAL BREAST CANCER, 2010, 10 (06) :489-491

[9]

Targeting the Hepatocyte Growth Factor-cMET Axis in Cancer Therapy [J].

Blumenschein, George R., Jr. ;

Mills, Gordon B. ;

Gonzalez-Angulo, Ana M. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (26) :3287-3296

[10]

HER2-positive gastric cancer [J].

Boku, Narikazu .

GASTRIC CANCER, 2014, 17 (01) :1-12

← 1 2 3 4 5 →